HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) All Versions of this Article: jcp.2006.041830v1 61/6/689    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Google Scholar Articles by Walker, R A PubMed PubMed Citation Articles by Walker, R A Pubmed/NCBI databases Medline Plus Health Information Breast Cancer Topic Collections Editor's choice

Immunohistochemical markers as predictive tools for breast cancer

Correspondence to:
Professor R A Walker, Department of Cancer Studies & Molecular Medicine, University of Leicester, Robert Kilpatrick Building, Leicester Royal Infirmary, PO Box 65, Leicester LE2 7LX, UK; raw14{at}le.ac.uk

Breast cancer is the predominant malignancy where oncologists use predictive markers clinically to select treatment options, with steroid receptors having been used for many years. Immunohistochemistry has taken over as the major assay method used for assessing markers. Despite its extensive use there are still issues around tissue fixation, methodology, interpretation and quantification. Although many markers have been evaluated, the oestrogen receptor remains the most reliable and best example of a predictor of treatment response. It is of major importance clinically that those undertaking interpretation of predictive markers understand the technical pitfalls and are aware of how expression of a particular marker relates to breast cancer pathology. A false negative or a false positive result will impact on patient management.